Literature DB >> 1607002

Pharmacokinetics of vinorelbine in man.

P Marquet1, G Lachatre, J Debord, B Eichler, F Bonnaud, G Nicot.   

Abstract

The pharmacokinetics of vinorelbine has been investigated by a new HPLC method in 8 cancer patients receiving 8 weekly doses (30 mg.m-2) administered by brief infusion (15 min). The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1). The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h). The pharmacokinetic parameters exhibited wide interindividual variations. The results are consistent with those of previous RIA studies, although the HPLC method appears to be more specific and more precise.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1607002     DOI： 10.1007/bf00314866

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Pharmacokinetics and metabolism of Navelbine.

Authors:  A Krikorian; R Rahmani; M Bromet; P Bore; J P Cano
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

2.  High-performance liquid chromatographic determination of navelbine in human plasma and urine.

Authors:  G Nicot; G Lachatre; P Marquet; F Bonnaud; J P Vallette; J L Rocca
Journal:  J Chromatogr       Date:  1990-06-08

3.  Standardization of symbols in clinical pharmacology.

Authors:  J K Aronson; H J Dengler; L Dettli; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.

Authors:  P Mangeney; R Z Andriamialisoa; N Langlois; Y Langlois; P Potier
Journal:  J Org Chem       Date:  1979-10-01       Impact factor: 4.354

5.  Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.

Authors:  P Boré; R Rahmani; J van Cantfort; C Focan; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).

Authors:  R Rahmani; R Bruno; A Iliadis; R Favre; S Just; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

7.  Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.

Authors:  R Rahmani; F Guéritte; M Martin; S Just; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).

Authors:  R Rahmani; M Martin; J Barbet; J P Cano
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701
  8 in total
  10 in total

1.  Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Authors:  W Voigt; T Kegel; M Weiss; T Mueller; H Simon; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

2.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.

Authors:  Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2010-11-11       Impact factor: 3.167

Review 3.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Authors:  T Schilling; H H Fiebig; S Kerpel-Fronius; B Winterhalter; P Variol; P Tresca; B Heinrich; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Osteonecrosis of the jaw related to sunitinib.

Authors:  Felix P Koch; Christian Walter; Torsten Hansen; Elke Jäger; Wilfried Wagner
Journal:  Oral Maxillofac Surg       Date:  2011-03

Review 7.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 8.  Vinorelbine--a clinical review.

Authors:  R K Gregory; I E Smith
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

9.  Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.

Authors:  K M Li; L P Rivory; S J Clarke
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

10.  Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis.

Authors:  Aurélie Pétain; Dafang Zhong; Xiaoyan Chen; Zhang Li; Shao Zhimin; Jiang Zefei; Grégoire Zorza; Pierre Ferré
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-27       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.